Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors), TNIK inhibitors(TRAF2 and NCK-interacting protein kinase inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 22 Mar 2024 |